4-[5-chloro-2-(1-hydroxybutan-2-ylamino)pyrimidin-4-yl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[5-chloro-2-(1-hydroxybutan-2-ylamino)pyrimidin-4-yl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]benzamide
• 化学式: C₂₃H₂₄Cl₂N₄O₃
• 分子量: 475.4
• InChiKey: PUBXHYAWRANLNN-ROPPNANJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME AGENTS ANTI-TUMEUR
  申请人：ASTRAZENECA AB

  公开号：WO2005026152A1

  公开（公告）日：2005-03-24

  A quinazoline derivative of the formula (I): (A chemical formula should be inserted here - please see paper copy enclosed) Formula I wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.

  一种喹唑啉衍生物的化学式（I）：（请参阅附上的纸质副本以获取化学式）化学式 I，其中取代基如文本中定义的那样，用于生产抗增殖作用，该作用通过在温血动物（如人）中部分或完全抑制erbB2受体酪氨酸激酶而产生。
• Protein kinase inhibitors and uses thereof
  申请人：——

  公开号：US20040106615A1

  公开（公告）日：2004-06-03

  Described herein are compounds that are useful as protein kinase inhibitors having the formulae I and V: 1 or a pharmaceutically acceptable salt thereof, wherein Ring B, Z 1 , Z 2 , U, T, m, n, p, Q, Q′, R 1 , R 2 , R x , R 3 , and R 6 are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation.

  本文描述了以下具有I和V式的蛋白激酶抑制剂化合物，或其药学上可接受的盐：其中环B、Z1、Z2、U、T、m、n、p、Q、Q′、R1、R2、Rx、R3和R6如本文所定义。这些化合物及其药学上可接受的组合物可用于治疗或减轻各种疾病的严重程度，包括中风、炎症性疾病、自身免疫性疾病，如SLE狼疮和银屑病、增殖性疾病，如癌症，以及与器官移植相关的疾病。
• PROTEIN KINASE INHIBITORS AND USES THEREOF
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP1546117A2

  公开（公告）日：2005-06-29
• QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS
  申请人：AstraZeneca AB

  公开号：EP1664029A1

  公开（公告）日：2006-06-07
• JP2007505874A
  申请人：——

  公开号：JP2007505874A

  公开（公告）日：2007-03-15